Next Article in Journal
Chest Compressions for Bradycardia during Neonatal Resuscitation—Do We Have Evidence?
Previous Article in Journal
Conducting Psychosocial Intervention Research among Adolescents and Young Adults with Cancer: Lessons from the PRISM Randomized Clinical Trial
Open AccessReview

Caffeine and Clinical Outcomes in Premature Neonates

Department of Pediatrics, University at Buffalo, Buffalo, NY 14203, USA
*
Author to whom correspondence should be addressed.
Children 2019, 6(11), 118; https://doi.org/10.3390/children6110118
Received: 24 July 2019 / Revised: 29 September 2019 / Accepted: 6 October 2019 / Published: 24 October 2019
Caffeine is the most widely used drug by both adults and children worldwide due to its ability to promote alertness and elevate moods. It is effective in the management of apnea of prematurity in premature infants. Caffeine for apnea of prematurity reduces the incidence of bronchopulmonary dysplasia in very-low-birth-weight infants and improves survival without neurodevelopmental disability at 18–21 months. Follow-up studies of the infants in the Caffeine for Apnea of Prematurity trial highlight the long-term safety of caffeine in these infants, especially relating to motor, behavioral, and intelligence skills. However, in animal models, exposure to caffeine during pregnancy and lactation adversely affects neuronal development and adult behavior of their offspring. Prenatal caffeine predisposes to intrauterine growth restriction and small growth for gestational age at birth. However, in-utero exposure to caffeine is also associated with excess growth, obesity, and cardio-metabolic changes in children. Caffeine therapy is a significant advance in newborn care, conferring immediate benefits in preterm neonates. Studies should help define the appropriate therapeutic window for caffeine treatment along with with the mechanisms relating to its beneficial effects on the brain and the lung. The long-term consequences of caffeine in adults born preterm are being studied and may depend on the ability of caffeine to modulate both the expression and the maturation of adenosine receptors in infants treated with caffeine. View Full-Text
Keywords: Caffeine; bronchopulmonary dysplasia; Premature infant; Newborn; Neuroprotection Caffeine; bronchopulmonary dysplasia; Premature infant; Newborn; Neuroprotection
Show Figures

Figure 1

MDPI and ACS Style

Kumar, V.H.; Lipshultz, S.E. Caffeine and Clinical Outcomes in Premature Neonates. Children 2019, 6, 118.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop